The world’s biggest pharmaceutical company, AstraZeneca, has been pushing for a vaccine that could protect people against Zika in Brazil.

A trial is being carried out in Brazil, and the trial is set to start on Monday.

The trial, called a phase 2 trial, aims to test the effectiveness of the vaccine in a large group of people, including pregnant women.

But there are some concerns about how the trial will proceed, with questions over the safety of the Zika vaccine, the safety and efficacy of the new Zika virus and the impact of the virus on the pregnant women who might receive the vaccine.

AstraZeneca is one of the biggest pharmaceutical companies in the world, with more than 300 pharmaceutical products and services.

It is the biggest drug maker in Brazil and one of several companies developing vaccines for Zika.

The trial is expected to take about two months.

The researchers are working on two vaccines: one to prevent microcephaly, a birth defect that affects the brains of babies.

The other is a vaccine to protect people from dengue fever, a viral disease that affects people of different ethnic groups in Latin America.

It is hoped that both vaccines will protect people who might become pregnant.

But the trial may not go as smoothly as Astra is hoping.

“The trial needs to be robust, with a clear outcome,” Astra said in a statement.

“If the trial fails, Astraprene could withdraw from the trial.”

But the company has said it is working on a second vaccine to prevent dengus.

For now, Astraza is hoping to secure a vaccine from a third company.

That company is a US company called Novartis.

Astra has not revealed who it is negotiating with, but Novartes is expected on Monday to announce a vaccine candidate.

Astra said that the vaccine candidate, called the AZZ-19B, is similar to the AZT-Z2A vaccine that was recently approved in Brazil to protect pregnant women against dengues.

Novartis said it was developing a vaccine for Zika that will target different types of mosquitoes.

If approved, the vaccine would be the first vaccine against Zika to be made from a human, animal or plant.

It could also help prevent diphtheria and tetanus.

As with any new vaccine, it is important to follow the guidelines set out by the World Health Organization (WHO) to make sure the vaccine is safe.

There is no official word on how long the trial would last, but Astra says the trial could end within weeks.

ABC News’ Ben Smith contributed to this report.